Clinical efficacy assessment and safety analysis of laparoscopic radiofrequency ablation in the treatment of advanced-stage pancreatic carcinoma

( views:317, downloads:0 )
Author:
ZHENG Qiang(Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Guangzhou Medical College, Guangzhou 510260, China)
XUE Ping(Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Guangzhou Medical College, Guangzhou 510260, China)
LU Hai-wu(Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Guangzhou Medical College, Guangzhou 510260, China)
CAO Liang-qi(Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Guangzhou Medical College, Guangzhou 510260, China)
WEN Zi-long(Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Guangzhou Medical College, Guangzhou 510260, China)
Journal Title:
Chinese Journal of Biomedical Engineering
Issue:
Volume 18, Issue 03, 2012
DOI:
10.3760/cma.j.issn.1674-1927.2012.03.012
Key Word:
Laparoscopes;Ablation techniques;Pancreatic neoplasms;Comparative effectiveness research;Security analysis

Abstract: Objective To investigate the efficacy and safety of laparoseopic radiofrequeney ablation (LRFA) in the treatment of advanced-stage pancreatic carcinoma.Methods Between April 2008 and May 2011,the clinical efficacy indications were retrospectively analyzed in 21 patients with advancedstage pancreatic carcinoma after LRFA treatment.Verbalratingscales (VRS) was used to evaluate the alleviation degree of pain.The postoperative serum total bilirubin was detected at day 1 and day 7 and postoperative CA19-9 level at day 7 and day 30.Moreover,the vital signs (such as body temperature),complications,peritoneal drainage,serum amylase and abdominal symptom were observed.B ultrasound were used to reexamine the recurrence of tumor after surgery.A following-up was done in patients in order to observe the postoperative survival period.Results The pain after surgery was alleviated in all the patients to different degrees as compared with that before surgery (preoperation 0~1:n=2; 2~3:n=19 vs postoperation 0~ 1:n=17 ; 2~3:n=4) (P<0.05).Both serun total bilirubin and CA 19- 9 were significantly decreased after surgery,with total bilirubin (103.23±22.34)μmol/L at day 7 and CA19-9 (170.71±95.64) U/ml at day 30 after surgery (all P<0.05 ).After surgery,the body temperatures were briefly elevated in patients,which were all decreased to normal after treatment.The peritoneal drainage liquid was most at day 1 after surgery (ranging from 10~180 ml) but gradually rcduced at day 3.Eight patients were found transient increase of serum amylase at day 1 after surgery,with serum amylase( 121.52±62.96)U/ml at day 7 after surgery,whose amylase preoperation was (110.80 ± 51.85) U/ml (P<0.05).No complication was found,such as intraperitoneal bleeding,abdominal abscess,gastrointestinal burning perforation,bilc lcakage and mesenteric venous thrombosis.The B ultrasound showcd thc total ablation in 15 cases and residual lesions in 6 cases.Mcan survival period was (11±3) months.Conclusion LRFA can effectively improve the pain,yellowness removal,with advantages of mini-invasion and safety.

  • [1]邵永孚.胰腺癌的分期及其依据临床外科杂志,2005,13:198-199.
  • [2]Mirza AN,Fornage BD,Sneige N,et al.Radiotrequency ablation of solid tumors.Cancer J,2001,7:95-102.
  • [3]Spiliotis JD,Datsis AC,Chatzikostas P,et al.Pancreatic cancer palliation using radiofrequency ablation.A new technique.Cancer Ther,2005,3:379-382.
  • [4]包善华,谢敏,张炜炜,等.射频消融治疗不能切除的胰体尾癌.消化外科,2006,5:95-97.
  • [5]Kayahara M,Nagakawa T,Ueno K,et al.An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging.Cancer,1993,72:2118-2123.
  • [6]Spiliotis JD,Datsis AC,Michalopoulos NV,et al.Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas.Langenbecks Arch Surg,2007,392:55-60.
  • [7]刘哲,张文智,姜凯,等.进展期胰腺癌射频消融治疗的安全性研究.中华肝胆外科杂志,2009,15:199-201.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn